What happened with Doctors Without Borders and Gilead?

Doctors Without Borders criticizes Gilead over HIV prevention drug access

Doctors Without Borders (Médecins Sans Frontières) sharply criticized Gilead for refusing to sell an HIV prevention drug directly to the organization. The dispute appears within a broader fight over access to preventive treatment options that can reduce new HIV infections.

In the reporting provided, the criticism is framed as “unconscionable” and centers on distribution terms. If an organization providing medical services cannot procure the drug directly, it may face delays or higher administrative hurdles, which can affect how quickly prevention programs reach communities that need them.

This matters because HIV prevention medicines are time-sensitive: scale-up depends on reliable supply and procurement pathways. When manufacturers limit sales channels, NGOs may have to rely on intermediaries or alternate mechanisms, which can introduce gaps in availability.

However, the provided stories do not include details on the specific drug, the reasons Gilead cited for refusing direct sales, or whether alternative access routes are currently being used.

Overall, the reporting highlights a common pattern in global health: even when a preventive therapy exists, access can hinge on commercial and contractual decisions rather than scientific capability alone.